Autoimmune lymphoproliferative syndrome epidemiology and demographics
|
Autoimmune lymphoproliferative syndrome Microchapters |
|
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune lymphoproliferative syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome epidemiology and demographics |
|
FDA on Autoimmune lymphoproliferative syndrome epidemiology and demographics |
|
CDC on Autoimmune lymphoproliferative syndrome epidemiology and demographics |
|
Autoimmune lymphoproliferative syndrome epidemiology and demographics in the news |
|
Blogs on Autoimmune lymphoproliferative syndrome epidemiology and demographics |
|
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Epidemiology and Demographics
Incidence
- The incidence of Autoimmune lymphoproliferative syndrome(ALPS) is unknown as many cases remain undiagnosed or misdiagnosed.[1]
Prevalence
- The prevalence is not known as many cases are left unidentified. So far 500 patients with ALPS have been identified coming from more than 300 families.[2]
Case-fatality rate/Mortality rate
- Mortality rate is 15% in patients with ALPS-FAS by age 50.[2]
Age
- Patients of all age groups may develop Autoimmune lymphoproliferative syndrome.[3]
- Typically ALPS appear in early childhood. The median age at diagnosis is 18 years.
Race
- There is no racial predilection to Autoimmune Lymphoproliferative Syndrome.
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Rao, V. Koneti; Oliveira, João Bosco (2011). "How I treat autoimmune lymphoproliferative syndrome". Blood. 118 (22): 5741–5751. doi:10.1182/blood-2011-07-325217. ISSN 0006-4971.
- ↑ 2.0 2.1 Shah, Shaili; Wu, Eveline; Rao, V. Koneti; Tarrant, Teresa K. (2014). "Autoimmune Lymphoproliferative Syndrome: an Update and Review of the Literature". Current Allergy and Asthma Reports. 14 (9). doi:10.1007/s11882-014-0462-4. ISSN 1529-7322.
- ↑ Price, Susan; Shaw, Pamela A.; Seitz, Amy; Joshi, Gyan; Davis, Joie; Niemela, Julie E.; Perkins, Katie; Hornung, Ronald L.; Folio, Les; Rosenberg, Philip S.; Puck, Jennifer M.; Hsu, Amy P.; Lo, Bernice; Pittaluga, Stefania; Jaffe, Elaine S.; Fleisher, Thomas A.; Rao, V. Koneti; Lenardo, Michael J. (2014). "Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations". Blood. 123 (13): 1989–1999. doi:10.1182/blood-2013-10-535393. ISSN 0006-4971.